Table 1.

Effect of Doxorubicin DOXO (2 or 10 mg/kg; i.p.) on left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), ejection fraction (% EF), and fraction shortening (% FS) after a single administration (1st group), two administrations (2nd group), or three administrations (3rd group). Results were expressed as mean ± S.E.M. from 6 mice/group.

Groups	Parameters	Control	2 mg/kg	10 mg/kg
1st group	LVEDD	3.97 ± 0.11	3.92 ± 0.11	4.09 ± 0.10
	LVESD	2.62 ± 0.17	2.77 ± 0.09	3.00 ± 0.06 *
	% EF	62.17 ± 4.1	58.39 ± 1.12 *	52.7 ± 1.38 **
	% FS	30.41 ± 0.72	33.26 ± 2.93	26.76 ± 0.92 *
2nd group	LVEDD	3.94 ± 0.05	3.87 ± 0.05	3.99 ± 0.06
	LVESD	2.78 ± 0.054	2.78 ± 0.05	2.90 ± 0.06*
	% EF	57.2 ± 1.25	54063 ± 1.6 *	53.73 ± 1.61 *
	% FS	30.41 ± 0.85	27.95 ± 1.06 *	27.43 ± 1.02 *
3rd group	LVEDD	3.86 ± 0.04	3.94 ± 0.07	3.96 ± 0.06 *
	LVESD	2.73 ± 0.15	2.85 ± 0.06	2.9 ± 0.14 *
	% EF	59.00 ± 4.17	54.4 ± 2.6 *	50.49 ± 4.79 **
	% FS	31.76 ± 1.68	30.97 ± 2.91	25.37 ± 3.02 *